Drug Trial Radar · NCT05011851
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jul 12, 2022
Primary completion
May 13, 2024
Study completion Jul 16, 2024
Sponsor
- Lead sponsor
- Neuren Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
Conditions
- Angelman Syndrome
Interventions
NNZ-2591Drug
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 13 weeks
- Pharmacokinetic - Typical AUC24 of 30kg ChildTime frame: 13 weeks
- Pharmacokinetic - Typical t1/2 in 30 kg ChildTime frame: 13 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sydney Children's Hospital
Randwick, New South Wales, Australia
Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service
South Brisbane, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.